Center for Personalized Diagnostics

Penn Medicine's Center for Personalized Diagnostics (CPD) utilizes massively parallel sequencing panels to simultaneously evaluate multiple targetable genes in cancer specimens. Supporting the clinical oncology team at Penn, our panels provide information to identify individualized therapies that can dramatically alter a patient's treatment course and outcome.

CPD currently offers the following gene panels (click tables for larger view):  

PennSeq^TM Hematologic Malignancies Panel

Sequence analysis of 116 genes

• Accepted Specimens: Blood; bone marrow; formalin-fixed, paraffin-embedded (FFPE) tissue; fresh tissue in PreservCyt
• Minimum Requirements: 10% tumor nuclei for tissue; 100ng DNA (non-FFPE), 200ng DNA (FFPE)
• Covers: Genes listed for the entire coding sequence +/- ~8bp flanking intronic sequence; two hotspots in the TERT promoter
• Detects: Single nucleotide variants (SNVs); small indels; copy number gains in ABL1, PDGFRA, and MYC
• Limitations: Lower limit of reportability 4% variant allele fraction (VAF) [1% for FLT3 ITDs only]. No deep intronic splice variants; no promoter variants outside of TERT; no structural rearrangements; no methylation; no copy number loss

The PennSeq assay enriches for many genomic regions and then is computationally filtered to report variants from a curated set of genes. Incidental variants may be discovered during routine review of the genomic data that fall outside of the curated set of genes. Any Disease-Associated or other potentially significant variant discovered incidentally will be included in the clinical report with a comment and appropriate interpretive text, as needed. By requesting this testing and accepting this report for clinical purpose, implied consent is given that information on incidentally identified genomic variants may be received.

 

PennSeq^TM Solid Tumor Panel 

Sequence analysis of 183 genes


• Accepted Specimens: Formalin-fixed, paraffin-embedded (FFPE) tissue; fresh tissue in PreservCyt
• Minimum Requirements: 10% neoplastic tissue; 100ng DNA (non-FFPE), 200ng DNA (FFPE)
• Covers: Genes listed for the entire coding sequence +/- ~8bp flanking intronic sequence; two hotspots in the TERT promoter
• Detects: Single nucleotide variants (SNVs); small indels; targeted copy number gains
• Limitations: Lower limit of reportability 4% variant allele fraction (VAF) [1% for FLT3 ITDs only]. No deep intronic splice variants; no promoter variants outside of TERT; no structural rearrangements; no methylation; no copy number loss

The PennSeq assay enriches for many genomic regions and then is computationally filtered to report variants from a curated set of genes. Incidental variants may be discovered during routine review of the genomic data that fall outside of the curated set of genes. Any Disease-Associated or other potentially significant variant discovered incidentally will be included in the clinical report with a comment and appropriate interpretive text, as needed. By requesting this testing and accepting this report for clinical purpose, implied consent is given that information on incidentally identified genomic variants may be received.

 

Fusion Transcript Panel

RNA sequencing analysis of 56 genes for rearrangements


• Accepted Specimens: Formalin-fixed, paraffin-embedded (FFPE) tissue; fresh tissue in PreservCyt
• Minimum Requirements: 10% neoplastic tissue
• Covers: Selected exon-intron boundaries
• Detects: Aberrant transcripts involving the included exons; can detect novel fusion partners at known break-points
• Limitations: Only detects fusions which include at least one of the targets at the included exons; no SNVs; no copy number changes; no small indels; no methylation

 

Penn Precision Panel 2.0

Sequence analysis of 59 genes


• Accepted Specimens: Formalin-fixed, paraffin-embedded (FFPE) tissue; fresh tissue in PreservCyt; blood; bone marrow
• Minimum Requirements: 10% neoplastic tissue
• Covers: Hotspots and the entire coding sequence of TP53
• Detects: Single nucleotide variants (SNVs); small indels
• Limitations: Lower limit of reportability 4% variant allele fraction; indels unreliable >20bp; no deep intronic splice variants; no structural rearrangements; no copy number variants; no methylation